−Removed: Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities.
−Removed: Market for Ordinary Shares
−Removed: The principal trading markets for the Company’s ordinary shares are the Global Select Market of The Nasdaq Stock Market LLC and the Equity Shares (Transition) category of the London Stock Exchange.
−Removed: The Company’s ordinary shares trade under the symbol “INDV” on both exchanges.
−Removed: Effective June 27, 2024, we have designated Nasdaq as our primary exchange.
−Removed: Based upon information supplied from our transfer agent, there were approximately 1,027 shareholders of record of our Ordinary Shares as of January 31, 2025.
−Removed: We have not paid any dividends during the past three fiscal years and do not anticipate declaring or paying any cash dividends on our ordinary shares in the foreseeable future.
−Removed: Under English law, any payment o f dividends would be subject to relevant legislation and our articles of association, which provide that payment of dividends be approved by our board of directors and, in some cases, our shareholders, and may only be paid from our distributable earnings available for the purpose, determined on an unconsolidated basis.
+Added: Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
+Added: Market for common stock
+Added: The principal trading market for the Company’s common stock is the Global Select Market of The Nasdaq Stock Market LLC.
+Added: The Company’s common stock trades under the symbol “INDV.”
+Added: Based upon information supplied from our transfer agent, there were approximately 139 stockholders of record of our common stock as of January 31, 2026.
+Added: We have not paid any dividends during the past three fiscal years and do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future.
+Added: Until January 23, 2026, we were incorporated under the laws of England and Wales and, under English law, any payment o f dividends would be subject to relevant legislation and our articles of association, which provide that payment of dividends be approved by our Board of Directors and, in some cases, our stockholders, and may only be paid from our distributable earnings available for the purpose, determined on an unconsolidated basis.
+Added: Five-Year Common Stock Performance
+Added: The following graph and table compare the cumulative total shareholder return of the Company’s common stock, the S&P 600 SmallCap Index, and the Nasdaq Biotech Index for the five-year period ended December 31, 2025.
+Added: The Company is a component of both indexes.
+Added: T he graph and table assume an initial investment of $100 was made on December 31, 2020 in each of the Company’s common stock and the two indexes, as well as reinvestment of all dividends without commissions.
+Added: Cumulative Total Stockholder Return
+Added: Amount Invested
+Added: Cumulative Total Return
+Added: As of/Through Dec.
+Added: 2020 2021 2022 2023 2024 2025
+Added: $ 100.00 $ 233.85 $ 301.40 $ 205.42 $ 167.21 $ 483.00
+Added: S&P 600 SmallCap Index $ 100.00 $ 126.77 $ 105.22 $ 119.71 $ 127.93 $ 133.00
+Added: Nasdaq Biotech Index $ 100.00 $ 100.48 $ 89.63 $ 92.95 $ 91.74 $ 121.00
Recent Sales of Unregistered Securities
Purchases of Equity Securities by the Issuer and Affiliated Purchases
−Removed: Period Total Number of shares purchased
+Added: Total Number of shares purchased
Average price paid per share
1 unchanged sentence
Maximum number of shares that may yet be purchased under the plans or programs
−Removed: 2,356,185 $8.89 2,356,185 7,417,125
−Removed: 1,486,660 $10.18 1,486,660 5,930,465
−Removed: 828,753 $11.53 828,753 5,101,712
−Removed: (1) Pursuant to that fourth share repurchase program announced July 25, 2024, for an aggregate purchase price up to no more than $100 million or 13,649,017 of ordinary shares, which program concluded on January 31 , 2025.
−Removed: (2) The average price paid per share on the London Stock Exchange was translated to U.S.
−Removed: dollars using the average exchange rate for the noted periods as follows:
−Removed: 31 (GB£1:U.S.$1.2699), Feb.
−Removed: 28 (GB£1:U.S.$1.2633), Mar.
−Removed: 1 to March 31 (GB£1:U.S.$1.2716), April 1 to April 30 (GB£1:U.S.$1.2529), May 1 to May 31 (GB£1:U.S.$1.2623), June 1 to June 30 (GB£1:U.S.$1.2724), July 1 to July 31 (GB£1:U.S.$1.2847), Aug.
−Removed: 31 (GB£1:U.S.$1.2916), Sept.
−Removed: 30 (GB£1:U.S.$1.3194), Oct.
−Removed: 31 (GB£1:U.S.$1.3081), Nov.
−Removed: 30 (GB£1:U.S.$1.2770), and Dec.
−Removed: 31 (GB£1:U.S.$1.2646).
Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.